Euro-Med Laboratories Phil., Inc.

PSE:EURO Stock Report

Market Cap: ₱3.1b

Euro-Med Laboratories Phil Past Earnings Performance

Past criteria checks 4/6

Euro-Med Laboratories Phil's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 1.4% per year. Euro-Med Laboratories Phil's return on equity is 5.8%, and it has net margins of 5.9%.

Key information

-2.4%

Earnings growth rate

-2.4%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate1.4%
Return on equity5.8%
Net Margin5.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Euro-Med Laboratories Phil makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

PSE:EURO Revenue, expenses and earnings (PHP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,0603551,3150
30 Jun 245,6323241,2610
31 Mar 245,3092951,2130
31 Dec 235,2642901,2090
30 Sep 234,8702561,1430
30 Jun 234,7172221,1340
31 Mar 234,5622111,0850
31 Dec 224,2242001,0250
30 Sep 223,6111751,0060
30 Jun 223,5791729860
31 Mar 223,5791699850
31 Dec 213,5871699910
30 Sep 213,5811931,0300
30 Jun 213,5342009670
31 Mar 213,4381919780
31 Dec 203,8292101,0450
30 Sep 205,6983311,3770
30 Jun 205,7963471,4280
31 Mar 205,9533831,4070
31 Dec 195,6883891,3340
31 Dec 185,2083741,1610
31 Dec 175,1433451,1010
31 Dec 164,8303051,0840
30 Sep 164,6992731,0000
31 Dec 154,4622329560
31 Dec 144,7042079370
31 Dec 134,5671899120

Quality Earnings: EURO has high quality earnings.

Growing Profit Margin: EURO's current net profit margins (5.9%) are higher than last year (5.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EURO's earnings have declined by 2.4% per year over the past 5 years.

Accelerating Growth: EURO's earnings growth over the past year (38.6%) exceeds its 5-year average (-2.4% per year).

Earnings vs Industry: EURO earnings growth over the past year (38.6%) exceeded the Pharmaceuticals industry 6.1%.


Return on Equity

High ROE: EURO's Return on Equity (5.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 13:59
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Euro-Med Laboratories Phil., Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution